Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
02/11/2026 01:18
BUZZ-Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591 ** Shares of Australia's Neuren Pharmaceuticals NEU.AX gain as much as 5.5% to A$21.480, their highest since August 26
** Stock is among the top gainers on the benchmark S&P/ASX 200 index .AXJO, which is down 0.3%
** Biopharma firm says the US FDA grants Orphan Drug designation for NNZ-2591 to treat neonatal hypoxic-ischemic encephalopathy, a brain injury caused when a baby's brain does not receive enough oxygen or blood flow
** Orphan drug designation qualifies the drugmaker for incentives, including tax credits for qualified clinical trials and exemption from FDA user fees
** NEU up 11.4% YTD
(Reporting by Keshav Singh Chundawat in Bengaluru)
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union